| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
2001-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dac8e8d008eafa862a19ebf0e494ae5 |
| publicationDate |
2004-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-522866-A |
| titleOfInvention |
A combination product comprising melagatran and a factor Xa inhibitor for anticoagulant therapy |
| abstract |
A combination product comprises (a) melagatran and (b) a Factor Xa inhibitor where each of (a) and (b) are formulated in admixture with a pharmaceutically-acceptable adjuvant and are present in synergistically anticoagulant effective amounts. The combination product can be used in the manufacture of a medicament for the treatment or prophylaxis of a condition where anticoagulant therapy is required. |
| priorityDate |
2000-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |